{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:09:40Z","timestamp":1768712980669,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800344"],"award-info":[{"award-number":["81800344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000385"],"award-info":[{"award-number":["82000385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2018A030313448"],"award-info":[{"award-number":["2018A030313448"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2020A1515011095"],"award-info":[{"award-number":["2020A1515011095"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021A1515010433"],"award-info":[{"award-number":["2021A1515010433"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.atherosclerosis.2022.01.013","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T20:31:34Z","timestamp":1642710694000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data"],"prefix":"10.1016","volume":"344","author":[{"given":"Xin","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-0454","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","article-title":"Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction","volume":"271","author":"Streng","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib4","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib5","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2020.08.061","article-title":"Proteomic signatures of heart failure in relation to left ventricular ejection fraction","volume":"76","author":"Adamo","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jchf.2020.02.007","article-title":"Myocardial infarction in heart failure with preserved ejection fraction: pooled analysis of 3 clinical trials","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib7","first-page":"742","article-title":"Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials","volume":"38","author":"Abdul-Rahim","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib10","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circualtion"},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib12","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1093\/eurheartj\/ehz427","article-title":"A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial","volume":"40","author":"Mehra","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib14","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","article-title":"Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF","volume":"6","author":"van Diepen","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","article-title":"Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease","volume":"140","author":"Branch","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib17","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.amjcard.2018.08.034","article-title":"Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 trial)","volume":"122","author":"Korjian","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib18","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/jamacardio.2019.1049","article-title":"Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the commander HF trial","volume":"4","author":"Greenberg","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.14309\/ajg.0000000000000572","article-title":"Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk","volume":"115","author":"Han","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00380-020-01554-8","article-title":"Association between sarcopenia and atherosclerosis in elderly patients with ischemic heart disease","volume":"35","author":"Uchida","year":"2020","journal-title":"Heart Ves."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib22","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1002\/ehf2.12951","article-title":"Independent link between peripheral artery disease and muscle wasting in patients with heart failure","volume":"7","author":"Ohori","year":"2020","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.atherosclerosis.2022.01.013_bib23","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur. J. Heart Fail."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022000272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022000272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:47:48Z","timestamp":1758156468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":23,"alternative-id":["S0021915022000272"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.01.013","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}